Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind study of guselkumab + golimumab combination therapy versus guselkumab, golimumab, and placebo in moderate to severe ulcerative colitis
MOH_2023-06-06_012486Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab, golimumab and guselkumab + golimumab in autoimmune colitis (6 arms), sponsored by Janssen Pharmaceutical. Started Mar 2023; status: active, not recruiting.
02
Drugs
guselkumabgolimumabguselkumab + golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-06-06_012486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-06_012486.